Get started

Stockssignals

MEDTECS SGX SELL/SHORT to 0.20-0.60 before BIG BUY! (UPDATE)TICKER CODE: 546 Company Name: Medtecs International Corporation Limited Industry: Medical Instruments & Supplies | Singapore Proposed Position: Sell Technical Analysis 1. Downwards Flag Pattern (Forming) 2. Downwards Fibonacci Retracement at 0.618 3. The market will more likely impulse downwards to test key levels before rising up 4. The flagpole take profit price range is on the market key levels Safe Exit: 1.25 1st Buy Entry: 0.60 2nd Buy Entry: 0.45 3rd Buy Entry: 0.20 - The market may test to this level (I doubt it will but it could) 1st Partial Take Profit: 2.40 2nd Partial Take Profit: 3.60 Stop Loss: 0.17 Again, I apologise to all my followers for the previous analysis. Please review and revert to this analysis and signals. As I did not consider and account for the downwards impulse and pullback! 🙇‍♂️🙇‍♂️
SGX:546Short
by traderprosignals
1
ARKK SELL/SHORT ALREADY ACTIVE to 60.50 - 82.50 (Next buy entry)TICKER CODE: ARKK Company Name: ARK Innovation ETF Industry: Financial | Exchange Traded Fund | USA Position Proposed: SELL Technical Analysis 1. Falling Wedge Pattern (Potentially forming) 2. Large Head & Shoulders (Completed) 3. Fibonacci Retracement at 0.786 is at the market key structure 4. Fibonacci Expansion Safe Take Profit Level 1 (Grey Zone) Also the length of Flagpole 5. Monthly chart was recently in the overbought range (will be looking for it to fall back in stable range, hence the fall) Analytical Assumption Monthly chart has not done any proper retracement to any market structure hence, we are looking for a deep pullback. This deep pullback will hit previous resistance which is now the new support Sell Exit: 110 (would be the nearest) Buy Entry: NOT READY (60.50-82.50) - Should be ready around August - End 2021 (will update entry potential on closer date) 1st Partial Take Profit: 190.20 (July-End 2022) 2nd Partial Take Profit: 270.00 (2023) All take profit may differ accordingly depending on available data (NOT ENOUGH AT THE MOMENT) Stop Loss: 50.5 This chart will be monitored and updated on a closer date or when more data is presented.
AMEX:ARKKShort
by traderprosignals
ARKG SELL/SHORT ALREADY ACTIVE to 37.00-42.85 (Next buy entry)TICKER CODE: ARKG Company Name: ARK Genomic Revolution ETF Industry: Financial | Exchange Traded Fund | USA Position Proposed: SELL Technical Analysis 1. Falling Wedge Pattern (Potentially forming) 2. Large Head & Shoulders (Completed) 3. Fibonacci Retracement at 0.786 is CLOSE BUT NOT AT key market structure 4. Fibonacci Expansion Safe Take Profit Level 1 (Grey Zone) Also the length of Flagpole 5. Monthly chart was recently in the overbought range (will be looking for it to fall back in stable range, hence the fall) Analytical Assumption Monthly chart has not done any proper retracement to any market structure hence, we are looking for a deep pullback. This deep pullback will hit previous resistance which is now the new support Sell Exit: 80.0 Buy Entry: NOT READY (37.00-42.85) - Should be ready around August - End 2021 1st Partial Take Profit: 135.00 (July-End 2022) 2nd Partial Take Profit: 193.00 (2023) All take profit may differ accordingly depending on available data (NOT ENOUGH AT THE MOMENT) Stop Loss: 34.5 This chart will be monitored and updated on a closer date or when more data is presented.
CBOE:ARKGShort
by traderprosignals
Li Auto Inc. BUY/LONG BIG POTENTIAL 16 to 45.25 By End 2021TICKER CODE: Li Company Name: Li Auto Inc. Industry: Consumer Cyclical | Auto Manufacturers | China Position Proposed: BUY Technical Analysis 1. Large Falling Wedge Pattern (Completed - Waiting for the break and retest) 2. Fibonacci Retracement at 0.786 (It has exceeded the range but on the monthly chart it is sitting on 0.786) 3. Fibonacci Expansion Safe Take Profit Level 1 (Grey Zone) Also the length of Flagpole The market will more likely than not breakout next week or today then do a small pullback (The pullback might not happen) Entry: NOW READY (16-22) 1st Partial Take Profit: 45.25 (August-End 2021) 2nd Partial Take Profit: 63.20 (Mid-End 2022)
NASDAQ:LILong
by traderprosignals
1
NNDM BUY/LONG BIG POTENTIAL INCOMING 4.60 to 21.30 by end 2021TICKER CODE: NNDM Company Name: Nano Dimension Ltd. Industry: Technology | Computer Hardware | Israel Position Proposed: BUY Technical Analysis 1. Large Falling Wedge (Forming) 2. Large Head & Shoulders 3. Fibonacci Retracement to reach 0.786 (Silver Zone) 4. Area of Confluence with 1 Trendline and Horizontal Support 5. Fibonacci Expansion Safe Take Profit Level 1 (Grey Zone) at the length of Flagpole Price Range 6. 2nd Take Profit is 80% Head Price Range of the 100% Price Range of the Head & Shoulders Buy Entry: NOT READY (4.60-4.80) 1st Partial Take Profit: 21.30 (November-End 2021) 2nd Partial Take Profit: 31.70 (Mid 2022) - Note that I would consider Full Take Profit Here Stop Loss: 2.55
NASDAQ:NNDMLong
by traderprosignals
3
TIGR BUY/LONG BIG POTENTIAL INCOMING 7.60 to 41.30TICKER CODE: TIGR Company Name: UP Fintech Holding Limited Industry: Financial | Capital Markets | China Position Proposed: BUY Technical Analysis 1. Large Falling Wedge (Forming) 2. Large Head & Shoulders 3. Fibonacci Retracement (Potentially) to reach 0.786 ( Silver Zone) 4. Fibonacci Expansion Safe Take Profit Level 1 (Grey Zone) at the length of Flagpole Price Range and also Trendline Resistance Level 5. 2nd Take Profit Level maybe a Head & Shoulders (NO FULL DATA ON 1st Shoulder) Buy Entry: NOT READY (7.60-9.50) 1st Partial Take Profit: 41.30 (November-End 2021) - Note that I would consider Full Take Profit Here 2nd Partial Take Profit: 62.00 (Mid 2022) - Note that we might not reach this Take Profit Stop Loss: 5.00
NASDAQ:TIGRLong
by traderprosignals
2
CHPT BUY/LONG NOW READY 23.00 to 59.00 By End 2021TICKER CODE: CHPT Company Name: ChargePoint Holdings, Inc. Industry: Consumer Cyclical | Specialty Retail | USA Position Proposed: BUY Technical Analysis 1. Falling Wedge / Pennant (Potentially breaking out soon) 2. Fibonacci Retracement at 0.786 ( Silver Zone) which is also sitting on the previous structure level 3 1st Take Profit will be at Fibonacci Expansion Safe Take Profit and Flagpole Length Entry: NOW READY (23.00=25.00) 1st Partial Take Profit: 59.00 (August-End 2021) 2nd Take Profit: 83.00 (Mid-End 2022)
NYSE:CHPTLong
by traderprosignals
4
$NNDM Target PTs 11.50-16Nano Dimension Ltd., together with its subsidiaries, provides additive electronics in Israel and internationally. Its flagship product is the proprietary DragonFly lights-out digital manufacturing (LDM) system, a precision system that produces professional multilayer circuit-boards, radio frequency antennas, sensors, conductive geometries, and molded connected devices for prototyping through custom additive manufacturing. The company also provides nanotechnology based conductive and dielectric inks; and DragonFly and Switch software to manage the design file and printing process. It markets and sells products and services to companies that develop products with electronic components, including companies in the defense, automotive, consumer electronics, semiconductor, aerospace, and medical industries, as well as research institutes. The company was founded in 2012 and is headquartered in Ness Ziona, Israel.
NASDAQ:NNDMLong
by UnknownUnicorn19246015
$XELA entry PT 1.70-1.85 PT 7 and higherExela Technologies, Inc. provides transaction processing solutions, enterprise information management, document management, and digital business process services worldwide. The company operates through three segments: Information & Transaction Processing Solutions (ITPS), Healthcare Solutions (HS), and Legal & Loss Prevention Services (LLPS). The ITPS segment provides lending solutions for mortgages and auto loans; banking solutions for clearing, anti-money laundering, sanctions, and interbank cross-border settlement; property and casualty insurance solutions for origination, enrollments, claims processing, and benefits administration communications; and public sector solutions for income tax processing, benefits administration, and records management. It also offers solutions for payment processing and reconciliation, integrated receivable and payables management, document logistics and location services, records management, and electronic storage of data/documents; and software, hardware, professional services, and maintenance related to information and transaction processing automation. The HS segment provides revenue cycle solutions, integrated accounts payable and accounts receivable, and information management for healthcare payer and provider markets. The LLPS segment processes legal claims for class action and mass action settlement administrations, involving project management support, notification, and outreach to claimants; and collects, analyzes, and distributes settlement funds. It also offers data and analytical services in the area of litigation consulting, economic and statistical analysis, expert witness services, and revenue recovery services for delinquent accounts receivable. The company is headquartered in Irving, Texas.
XLong
by BADQOMOCAWGOWLD
$BRPA entry PTs 31-33 PT 62-70 and higher...SPACsClinically proven COVID therapeutic Clinically proven COVID therapeutic BRIAN ALTERIO Bellefonte In my research, I have found that the Zyesami/Aviptadil COVID-19 therpeautic has proven successful in meeting primary and secondary enpoints, preventing people who are critically ill from the virus from dying. The success is based on Phase II and Phase III trials. Therapeutic trials were conducted by NeuroRx, a private company based here in Pennsylvania. The terapeutic’s owner, Relief Therapeutics (ticker: RLFTF) is a Geneva, Switzerland-based company. The FDA has had access to the complete trial data set for nearly a month now, and regardless of Zyesami/Aviptadil’s proven efficacy, the FDA is seemingly dragging its feet, while thousands of people continue to NEEDLESSLY die EVERY day, who could potentially be saved by this therapeutic. Zyesami/Aviptadil achieved both statistical and clinical significance in meeting ALL of its primary and secondary endpoints. The p-values demonstrating statistical significance were extremely low, which means the likelihood of these results occurring by random chance are also extremely low. Additionally, people who received Zyesami/Aviptadil went home from the hospital an average of 11 to 13 days sooner than people who received the placebo, which in this case was SOC (“standard of care”) that included the treatment Remdesivir. We have seen Big Pharma’s vaccines get pushed through the EUA process with relative ease and “lightning speed,” for the FDA…we’re talking just a couple of weeks for some of them, and some of which, I might add, are now halted due to blood clotting concerns…while the proven safe and successful therapeutic Zyesami/Aviptadil waits indefinitely on the sidelines for its EUA to begin saving people here in the States, and elsewhere in the world. (You can form your own opinions as to why that’s happening.) The trial’s results are readily available for review online…all you have to do is search for it. This story is too important to turn a blind eye to. Please, get this story covered and reported.
BLong
by BADQOMOCAWGOWLD
$50 MILLION REGISTERED DIRECT OFFERING case study$VISL ANNOUNCES $50 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES $VISL today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 18,181,820 shares of its common stock and common stock warrants to purchase up to 9,090,910 shares of common stock at a combined purchase price of $2.75 per share in a registered direct offering. The common stock warrants will be immediately exercisable, have an exercise price of $3.25 per share and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about February 8, 2021, subject to the satisfaction of customary closing conditions. finance.yahoo.com ANNOUNCES CLOSING OF $50 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES finance.yahoo.com What we can learn from the registered direct offerings?
NASDAQ:VISL
by AlenCiken
1
$DYNT Announces Extension of Key Distribution AgreementDynatronics Corporation Announces Extension of Key Distribution Agreement Bird & Cronin Renews Group Purchasing Agreement with Intalere for Orthopedic Soft Goods and Bracing Dynatronics announced today that its wholly-owned subsidiary, Bird & Cronin, LLC, renewed its purchasing agreement with Intalere, one of the leading national group purchasing organizations in the healthcare industry. The new agreement which extends the partnership through January 2024. Intalere members will receive negotiated pricing on our full line of orthopedic bracing solutions for spine, upper and lower extremities including key products such as the Sprint® air walker boot and U2TM wrist brace. With more than 100,000 members from healthcare organizations all over the country, Intalere members make nearly $9 billion in purchases annually. finance.yahoo.com
D
by AlenCiken
$UAMY Announces Receipt of Warning Letter from NYSE AmericanUnited States Antimony Corporation Announces Receipt of Warning Letter from NYSE American The basis for the Letter is that the Company sold shares of its common stock in a manner that violated Sections 301 and 713 of the Company Guide. Trading in the Company's common stock has been halted since before the opening of trading on Wednesday, February 17, 2021, as NYSE Regulation has assessed these rule violations. The violations relate to two non-underwritten transactions involving the sale of an aggregate of 26,290,000 shares of common stock at a discount to the market price at the time of each transaction, with the first transaction, which closed on February 3, 2021, involving the sale of 15,300,000 shares of common stock at a purchase price of $0.70 per share, and with the second transaction, which closed on February 16, 2021, involving the sale of 10,990,000 shares of common stock at a purchase price of $1.30 per share. In light of the very close proximity in time of the two transactions and the fact that both transactions involved substantially the same group of purchasers, NYSE Regulation determined that these issuances should be aggregated for purposes of Section 713 of the Company Guide. Together, the two transactions covered approximately 34.4% of the common stock outstanding. Section 301 of the Company Guide states that a listed company is not permitted to issue, or to authorize its transfer agent or registrar to issue or register, additional securities of a listed class until it has filed an application for the listing of such additional securities and received notification from the NYSE American that the securities have been approved for listing. Section 713 of the Company Guide requires shareholder approval when additional shares to be issued in connection with a transaction involve the sale, issuance, or potential issuance of common stock (or securities convertible into common stock) equal to 20% or more of presently outstanding stock for less than the greater of book or market value of the stock. As stated in the Letter, the Company failed to submit a completed listing application in advance of the February 16, 2021 transaction to obtain advance approval as required by Section 301 of the Company Guide and also did not obtain shareholder approval for the aggregate issuance of 26,290,000 shares that exceeded 20% of the common stock of the Company outstanding as required by Section 713 of the Company Guide. NYSE Regulation noted in the Letter that, after it became aware that the Company had entered into a purchase agreement in relation to the second transaction, NYSE Regulation informed representatives of the Company that it would be a violation of the applicable NYSE American rules for the Company to close the second transaction without first obtaining shareholder approval . Notwithstanding this clear guidance from NYSE Regulation, the Company went ahead with closing the transaction without notifying the Exchange. The Company has been advised by NYSE Regulation that the Company's common stock will resume trading on the NYSE American following the issuance of this press release and the filing of a Current Report on Form 8-K disclosing the receipt of the Letter, which the Company anticipates will be prior to the open of trading on Friday, February 19, 2021. finance.yahoo.com
AMEX:UAMY
by AlenCiken
Why $CTIB stock soared yesterday?investors also need to note that there has been no news regarding Yunhong this morning that could have triggered such a move. It appears that the Yunhong stock is a target of users across social media platforms like StockTwits, Reddit, Facebook, and Twitter. Investors are buying up the stock in order to force short sellers to cover their positions and when that happens, the stock price usually rises further. Hence, it might be a good idea for investors to keep an eye on the Yunhong stock this morning. ownsnap.com
C
by AlenCiken
Shares of $VIOT surges due to hype in social mediaShares of $VIOT SURGES higher due to the uptick in discussions about this stock has been surging on social media platforms like Reddit, Twitter, StockTwits, Facebook, and Discord. In a StockTwits post, Insider-Analysis.com pointed out that 7 institutions increased their positions in the stock while 3 decreased as of this past quarter. There is also a bullish report published about the company at Xueqiu.com. After translating the article to English, I read that Xueqiu believes that VIOT is expected to grow 10x this year due to its leadership position in appliances and Internet of Things devices. VIOT was also listed on a number of day trading watch lists on Reddit. And VIOT was listed in the “Daily Movers” on the Robinhood trading platform — which also added to the momentum of this shares. pulse2.com
NASDAQ:VIOT
by AlenCiken
Why $BRN skyrocketed in January?Barnwell Industries Reaches Agreement With MRMP Stockholders to End Potential Proxy Contest $BRN is pleased to announce today that it has entered into a cooperation and support agreement with MRMP Stockholders, with respect to the potential proxy contest pertaining to the election of directors to our Board of Directors (the “Board”). the Company will nominate its current slate of directors, which includes three of the MRMP nominees and two new independent directors elected in 2020, to stand for reelection to the Board at the upcoming 2021 annual meeting of stockholders. The MRMP Stockholders have agreed to vote their shares of common stock of the Company in favor of the election of the designated slate, and the MRMP Stockholders have agreed to withdraw their proposed slate of directors. I’m gratified that the Board of Directors will be unchanged from last year and be able to continue its efforts to move the Company forward. The agreement that we have forged with the Company should avoid distraction and unnecessary expense allowing our Board to continue to position Barnwell for long term positive cash generation and further share price appreciation.” finance.yahoo.com
AMEX:BRN
by AlenCiken
Why $ELYS Game Technology soared in 2021Why Elys Game Technology soared in 2021 On november 25. Company Announced Appointment of Senior Gaming Industry Executive Matteo Monteverdi to CEO. Matteo has been leading world-class B2B and B2C teams in the technology and digital industry for over 20 years between Silicon Valley and Boston. He spent the last decade of his career at the intersection of social gaming, digital betting, i-gaming and media working for international organizations in high growth segments. finance.yahoo.com Elys Game Technology Revenue Increases 44% to $9.7 Million for the Third Quarter of 2020 finance.yahoo.com
E
by AlenCiken